California-based Ionis Pharmaceuticals (IONS) is focused on the discovery and development of RNA-targeted therapies using its proprietary platform for itself and its partners. It uses this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases. Despite marketing no wholly-owned drug in its portfolio, IONS enjoys a diverse stream of revenues, including commercial products and royalties and numerous sources of collaborative and R&D revenues. Th ...